316 - In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized ESBL and Carbapenemase positive Subsets Causing Urinary Tract Infections in the United States (2019-2022)

Friday, October 18, 2024

12:15 PM – 12:20 PM US PT

Location: Halls JK - Arena 1

Rapid Fire Presenter(s)

Rodrigo E. Mendes, PhD (he/him/his)

Director
Element, Iowa City (JMI Laboratories)
North Liberty, IA, United States

Co-Author(s)

AS

Abigail Scullin, BS

Element Materials Technology/Jones Microbiology Institute
North Liberty, Iowa, United States
HK

Hank Kimbrough, PhD

Element Materials Technology/Jones Microbiology Institute
North Liberty, Iowa, United States
CH

Cory Hubler, BS

Element Materials Technology/Jones Microbiology Institute
North Liberty, Iowa, United States
RK

Renuka Kapoor, PhD

Scientific Investigator
GSK
Atlanta, Georgia, United States
DT

Didem Torumkuney, PhD

Scientific Director
GSK
Brentford, England, United Kingdom
SA

S J Ryan Arends, PhD (he/him/his)

Associate Director
JMI Laboratories / Element
North Liberty, Iowa, United States

Disclosure(s):

Rodrigo E. Mendes, PhD: JMI: RM is an employee of JMI. JMI was contracted by and received financial support from GSK to conduct gepotidac; Paratek Pharmaceuticals: Advisor/Consultant, Grant/Research Support

Hank Kimbrough, PhD: No financial relationships to disclose

Renuka Kapoor, PhD: GSK: Employee, Stocks/Bonds (Public Company)

Didem Torumkuney, PhD: GSK: Employee, Stocks/Bonds (Public Company)

S J Ryan Arends, PhD: No financial relationships to disclose